Table 2 Change in characteristics at week 12.

From: Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms

 

Placebo

n = 62

Empagliflozin

n = 62

SBP (adjusted mean over 24 h), mmHg

147.5 (0.77)

144.3 (0.77)

Change from baseline

0.41 (0.23)

− 7.73 (0.23)

Difference vs. placebo

 

− 8.14 (1.01)

95% CI

 

− 10.32, − 3.96

P

 

0.005

DBP (adjusted mean over 24 h), mmHg

94.4 (0.68)

89.1 (0.68)

Change from baseline

0.14 (0.09)

− 5.13 (0.09)

Difference vs. placebo

 

− 5.27 (0.07)

95% CI

 

− 8.19, − 1.35

P

 

< 0.001

SBP (office measurement), mmHg

155.0 (0.78)

147.9 (0.78)

Change from baseline

− 0.36 (0.12)

− 6.63 (0.13)

Difference vs. placebo

 

− 6.27 (0.11)

95% CI

 

− 9.37, − 1.97

P

 

< 0.001

DBP (office measurement), mmHg

96.4 (0.70)

90.9 (0.70)

Change from baseline

− 0.07 (0.09)

− 4.54 (0.09)

Difference vs. placebo

 

− 4.47 (1.01)

95% CI

 

− 7.41, − 0.47

P

 

< 0.001

HbA1c, %

7.6 (0.07)

7.4 (0.07)

Change from baseline

0.1 (0.09)

− 0.5 (0.09)

Difference vs. placebo

 

− 0.6 (0.11)

95% CI

 

− 0.83, − 0.42

P

 

< 0.001

Body weight, kg

76.4 (0.61)

79.6 (0.61)

Change from baseline

− 1.2 (0.99)

− 7.9 (0.99)

Difference vs. placebo

 

− 6.7 (0.86)

95% CI

 

− 8.45, − 5.03

P

 

< 0.001

HOMA-IR

4.9 (0.15)

4.5 (0.15)

Change from baseline

− 0.3 (0.09)

− 1.8 (0.09)

Difference vs. placebo

 

− 1.5 (0.12)

95% CI

 

− 1.90, − 1.06

P

 

< 0.001

Back to article page